Investigating a New Treatment Plan for DKA
Diabetic Ketoacidosis (DKA) is a serious complication of diabetes that occurs when the body produces high levels of ketones which causes the blood to be more acid than is normal. This can be triggered by infection or other illness. It can be life threatening and treatment requires hospitalization with IV (intravenous) fluids and insulin therapy.
The usual treatment of DKA is to give regular insulin intravenously based on a sliding scale relative to their blood glucose level in addition to other standard supportive care therapies. We would like to investigate if a different (novel) scale for insulin therapy is more effective. This novel administration protocol more closely mimics the insulin regimen in human medicine. Our goal is to find a protocol that results in faster resolution of the DKA state which would result in shorter hospitalization times and lower costs to owners.
Eligibility: Most dogs seen at the Cornell University Hospital for Animals who are diagnosed with DKA will be eligible.
Compensation: A $516 credit will be applied to your bill upon allowing us to send a copy of the itemized bill to the sponsor. You will receive 10% off your hospitalization costs for the study visit.
Owner Responsibilities: There are no responsibilities for this study outside of the hospital stay required to treat your dog's DKA.
Sponsorship: This study is being run with Iowa State University.
Principal Investigators: Dan Fletcher, PhD, DVM, DACVECC, John Loftus, PhD, DVM, DACVIM (SAIM)
Contact/Schedule an Appointment: Please contact the internal medicine service, the emergency service, or the clinical trials coordinator at 607.253.3060, or email email@example.com. Your referring veterinarian may also contact the hospital to refer your pet.